Biogen

Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
BioSpace
Eisai
Biogen
Alzheimer's disease
Leqembi
amyloid beta
Flag link:
JAMA: Leqembi could cost Medicare up to $5B per year
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Biogen
Eisai
Leqembi
drug pricing
Medicare
Alzheimer's disease
JAMA
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations
Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations
BioSpace
Biogen
Novartis
Sanofi
earnings
R&D
Flag link:
Biogen chalks up a Tecfidera patent win in Europe after losing US protections
Biogen chalks up a Tecfidera patent win in Europe after losing US protections
Fierce Pharma
Biogen
Tecfidera
multiple sclerosis
Europe
Flag link:
Biogen paid CEOs Viehbacher, Vounatsos $57M in 2022
Biogen paid CEOs Viehbacher, Vounatsos $57M in 2022
Medical Marketing and Media
Biogen
Pharma CEOs
executive compensation
Flag link:
Will Biogen’s Qalsody Be a Catalyst for Gene-Specific ALS Research?
Will Biogen’s Qalsody Be a Catalyst for Gene-Specific ALS Research?
BioSpace
Biogen
Qalsody
tofersen
ALS
drug development
R&D
Flag link:
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
CNBC
Biogen
earnings
Pharma CEOs
Chris Viehbacher
Eli Lilly
Alzheimer's disease
Leqembi
donanemab
Flag link:
FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS
FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS
Medical Marketing and Media
Biogen
Ionis Pharmaceuticals
ALS
tofersen
FDA
Flag link:
Busy with 3 program launches this year, Biogen trims pipeline
Busy with 3 program launches this year, Biogen trims pipeline
Fierce Biotech
Biogen
stroke
gene therapy
ophthalmology
earnings
Flag link:
Finding the big spenders beyond big pharma
Finding the big spenders beyond big pharma
EP Vantage
R&D
Amgen
Bayer
Biogen
Gilead Sciences
Merck KGaA
Moderna Therapeutics
Novo Nordisk
Regeneron Pharmaceuticals
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Biogen buys into Denali’s amyloid beta program
Biogen buys into Denali’s amyloid beta program
Pharmaphorum
Biogen
Denali Therapeutics
Alzheimer's disease
Flag link:
In Another Round of Cuts, Biogen Lays Off Unspecified Number of Employees
In Another Round of Cuts, Biogen Lays Off Unspecified Number of Employees
BioSpace
Biogen
layoffs
Flag link:
5 FDA decisions to watch in the second quarter
5 FDA decisions to watch in the second quarter
BioPharma Dive
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biogen
tofersen
ALS
Seres Therapeutics
C. difficile
Pfizer
GSK
vaccines
RSV
Regeneron
Eylea
Flag link:
Go or no go? Seagen's Padcev eyes FDA approval
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Flag link:
Massachusetts judge dismisses lawsuit against Biogen over failed launch of Alzheimer's drug Aduhelm
Massachusetts judge dismisses lawsuit against Biogen over failed launch of Alzheimer's drug Aduhelm
Endpoints
Massachusetts
Biogen
Aduhelm
legal
Flag link:
Biogen Successfully Targets Tau in Phase Ib Alzheimer's Study
Biogen Successfully Targets Tau in Phase Ib Alzheimer's Study
BioSpace
Biogen
Alzheimer's disease
clinical trials
Flag link:
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Investors Business Daily
Ionis Pharmaceuticals
Biogen
ALS
FDA
tofersen
Flag link:

Pages